WO1998053825A1 - Analgesic drug composition containing a capsaicinoid and potentiator therefor - Google Patents
Analgesic drug composition containing a capsaicinoid and potentiator therefor Download PDFInfo
- Publication number
- WO1998053825A1 WO1998053825A1 PCT/US1998/010769 US9810769W WO9853825A1 WO 1998053825 A1 WO1998053825 A1 WO 1998053825A1 US 9810769 W US9810769 W US 9810769W WO 9853825 A1 WO9853825 A1 WO 9853825A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- analgesic
- capsaicinoid
- drug composition
- foam layer
- analgesia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Definitions
- This invention relates to analgesic drugs and methods of inducing analgesia. More particularly, this invention relates to an analgesic drug containing, as an analgesic component, at least one capsaicinoid and, as a potentiator for the capsaicinoid, dextromethorphan, dextrorphan and/or pharmaceutically acceptable salt thereof.
- Capsicum oleoresin an extract of capsicum (dried red pepper and other species of the genus Capsicum such as Capsicum frutescens and Capsicum annum), contains the capsaicinoid capsaicin (tr ⁇ /w-8-methyl-N-vanillyl-6- noneamide). Both capsicum oleoresin and capsicum have for many years been used in a variety of over-the-counter topical analgesic medications such as HEET,
- 3,880,996 which discloses a topically administered analgesic composition for the symptomatic relief of localized pain of musculo-skeletal etiology containing, inter alia, capsicum oleoresin.
- Capsaicin enhances the release of substance P from neurons preventing its reaccumulation. As a result of this effect, capsaicin is believed to render skin insensitive to pain by depleting substance P from peripheral sensory neurons. See, Jessell et al., "Capsaicin- induced depletion of substance P from primary sensory neurones", Brain Research,
- capsaicin and an opioid analgesic such as morphine, codeine, hydromorphone, oxycodone, hydrocodone, oxymorphone, propoxyphene, levorphanol, meperidine, fentanyl, methadone, pentazocine, butorphanol and nalbuphine are disclosed in U.S. Patent No.
- Delivery vehicles for topically administered drugs such as capsaicin and capsicum include the gels disclosed in U.S. Patent Nos. 5,178,879, 5,306,504 and 5,420,197.
- a non-occlusive adhesive patch for the topical administration of capsicum or other topical medication is disclosed in U.S. Patent No. 5,536,263 and in commonly assigned copending U.S. patent application Serial No. 08/675,348, filed July 3, 1996.
- Dextromethorphan is a common ingredient of cough, cold and flu medications due to its antitussive (cough-suppressing) activity. Dextromethorphan is widely and authoritatively regarded as lacking analgesic activity, one of several pharmacological properties that distinguishes it from the opiate analgesics of the morphine type to which it is structurally related. Thus, Goodman and Gilman's "The Pharmaceutical Sciences", 17th ed., Mack Pub. (1985), page 870 states that "unlike codeine, [dextromethorphan] is devoid of analgesic properties...
- dextromethorphan Even the antitussive effects of dextromethorphan differ from those of the opioid analgesics; thus, e.g., the antitussive effects of the opioid analgesic codeine are antagonized by naloxone but those of dextromethorphan are not. And, unlike the opioid analgesics, dextromethorphan poses so little risk of abuse that it is specifically stated to be a non-scheduled drug (21 U.S.C. ⁇ 811(g)(2)). The few known exceptions to dextromethorphan' s lack of analgesic activity involve specific pain conditions, e.g., mouth pain as disclosed in U.S. Patent No.
- analgesic drug composition containing, as an analgesic component, a capsaicinoid such as capsaicin and, as a potentiator for the capsaicinoid, dextromethorphan, its active metabolite dextrorphan and/or pharmaceutically acceptable salt thereof.
- a capsaicinoid such as capsaicin
- an analgesic drug composition comprising an analgesia-inducing amount of at least one capsaicinoid possessing analgesic activity and an analgesia-potentiating amount of at least one analgesic potentiator selected from the group consisting of dextromethorphan, dextrorphan and pharmaceutically acceptable salts thereof.
- analgesia-inducing amount as applied to the capsaicinoid component of the foregoing drug composition shall be understood to mean an amount of capsaicinoid which when administered by itself or in combination with the analgesic potentiator provides significant analgesic effect.
- FIG. 1 is a cross-sectional view of a nonocclusive drug delivery system which can be used for the topical administration of the analgesic drug composition of this invention.
- R is selected from the group consisting of OH and OCH 3
- R 2 is selected from the group consisting of OH and o
- R 3 is selected from the group consisting of a C r C 4 alkyl, phenyl and methyl
- X is selected from the group consisting of o o o s o o
- NHC —NHCO—, NHCNH, NHCNH, NHS, or CNH,
- R is selected from the group consisting of a C 5 -C n alkyl, C 5 -C u alkenyl, C ⁇ - C 23 cis alkenyl, Cn-C ⁇ alkynyl, C-C ⁇ alkadienyl and Cu-C ⁇ methylene substituted alkane.
- Preferred capsaicinoids of the foregoing structure include those wherein both R, and R 2 are OH and X is
- R 3 CO and X is CNH, NHC or NHCNH.
- Preferred R groups include C 7 -C 10 alkyls and trans alkenyls, and C, 6 - Cj ! cis alkenyls and alkadienyls.
- the preferred moieties within these groups include C 8 H 17 , C 9 H 17 and C 17 H 33 .
- Preferred capsaicinoids include N-vanillyl- alkadienamides, N-vanillyl-alkanedienyls, and N-vanillyl-cis-monounsaturated alkenamides.
- capsaicinoids that are preferred for use herein are capsaicin (tr ⁇ /w-8-me yl-N-vanillyl-6-noneamide) or capsaicin-containing substance such as capsicum oleoresin and capsicum, synthetic capsaicin (N- vanillylnonanamide), the N-[(substituted phenyl)methyl] alkynylamides of U.S. Patent No. 4,532,139, the methylene substituted-N-[(substituted phenyl)methyl]- alkanamides of U.S. Patent No.
- capsaicin is the most preferred.
- the selected capsaicinoid component of the analgesic drug composition of this invention is potentiated by dextromethorphan, dextrorphan or pharmaceutically acceptable salt thereof, e.g., such acid addition salts as dextromethorphan hydrobromide and dextrorphan hydrobromide.
- dextromethorphan hydrobromide is preferred due to its ready commercial availability and long history of use in numerous over-the-counter medications.
- the analgesic drug composition of this invention must contain an analgesia-inducing amount of capsaicinoid(s), considered to be that amount of capsaicinoid(s) which, if administered alone, will provide significant analgesic effect or, if below that amount, when administered with the analgesic potentiator will provide significant analgesic effect.
- the analgesic potentiator component of the drug composition herein permits the capsaicinoid to be present in an amount which would be ineffective or at best only marginally effective to induce analgesia were it to be administered alone or, if the capsaicinoid is already at a level which by itself would provide significant analgesic effect, the presence of the potentiator will result in a significant increase in the level and/or duration of analgesia.
- the drug composition herein when intended for administration to adult humans can contain from about 0.02 to about 1.0, and preferably from about 0.025 to about 0.05, weight percent capsaicinoid(s).
- analgesia potentiator present in the analgesic drug composition of this invention must be at least that which is effective to significantly increase the analgesic effectiveness of the capsaicinoid.
- doses of the analgesic potentiator can vary from about 0.2 to about 2, and preferably from about 0.5 to about 1.0, weight percent.
- the analgesic drug composition of this invention can contain one or more additional drug components, e.g., an analgesic of the opioid type as disclosed in U.S. Patent No.
- the analgesic drug composition can be formulated for oral, parenteral, topical, etc., administration.
- a variety of pharmaceutically-acceptable carriers can be used to prepare the formulations. These include solid or liquid fillers, diluents, hydrotropes, surface-active agents, and the like.
- the amount of carrier employed in conjunction with the capsaicinoid and analgesic potentiator will be such as to provide a practical quantity of these drugs per unit dose.
- the drug composition of this invention is especially useful for the treatment of such pains as neuralgias, rheumatoid arthritis, bursitis, myositis, integumental pain, etc., for which it is administered as a topical preparation, preferably in combination with a penetration enhancer.
- the drug composition can be formulated as a liquid, paste, ointment, cream, lotion, or gel, e.g., any of the gels disclosed in U.S. Patent Nos. 5,178,879, 5,306,504 and 5,420,197.
- the following oleophilic topical ointment provides generally acceptable results:
- the analgesic drug composition can be administered via a nonocclusive adhesive patch, e.g., as disclosed in U.S. Patent No. 5,536,263 and preferably as disclosed in commonly assigned copending U.S. patent application Serial No. 08/675,348, filed July 3, 1996.
- the drug delivery device includes a substantially moisture vapor permeable, liquid impermeable, flexible thermoplastic barrier layer 11 bonded to, and generally coextensive with, upper surface 12 of open cell, flexible, oleophilic thermoplastic resin foam layer 13.
- Pressure sensitive adhesive 14 occupies a zone, or stratum, 15 on lower surface 16 of foam layer 13 for securing the drug delivery device to the skin.
- a release liner 17 seals and protects lower surface 16 of the foam layer during the residency of drug delivery device 10 within its package.
- the minimum strength of the bond between barrier layer 11 and foam layer 13 must be sufficient to prevent or inhibit separation, i.e., delamination, of the barrier layer from the foam layer under the sort of flexing and/or stretching forces that may be encountered during the useful life of the applied device.
- bond strengths of at least about 2 newtons (N), preferably at least about 3 N and more preferably at least about 5 N will generally provide satisfactory results in this regard.
- the bond between layers 11 and 13 may be achieved, it is necessary that the bond itself not result in a significant reduction in the moisture vapor transmission rate (MVTR) of the assembled layers.
- MVTR moisture vapor transmission rate
- the MVTR of the barrier layer-foam layer subassembly will be at least about 500, preferably at least about 1000 and more preferably at least about 1200, g/m 2 /24 h at 100% r.h. and 32°C as measured by ASTM F1249-90.
- barrier layer 11 Another requirement of drug delivery device 10 is that whatever the bond strength between barrier layer 11 and foam layer 13, the contact adhesive must impart a peel strength to the drug delivery device, i.e., the amount of force required to peel the spent drug delivery device from the skin, which is less, preferably at least about 20 percent less and more preferably at least about 40 percent less, than such bond strength in order to prevent or minimize the separation of the barrier layer from the foam layer when the spent drug delivery device is peeled from the skin.
- Barrier layer 11 can be any thermoplastic film possessing an MVTR of one of the aforestated values.
- the barrier layer can be a polyurethane film possessing an average thickness of from about 0.5 to about 3.5 mils and preferably from about 1.0 to about 1.5 mils and a tensile strength of at least about 2500 psi and preferably at least about 3500 psi.
- Foam layer 13 in its as-manufactured state is an open cell, flexible, oleophilic foam that provides a stable matrix for the analgesic drug composition herein particularly when the drug is formulated in an oleophilic delivery vehicle.
- stable matrix is meant that property of the foam which, owing to its oleophilic character, enables the foam to function not only as a depot, or reservoir, for the oleophilic drug composition, but confines the composition to zone 19 which is separated by barrier zone 20 from zone 15 occupied by pressure sensitive adhesive 14.
- the oleophilic characteristics of the foam layer prevent or inhibit migration of drug composition 18 into adhesive zone 15 where it could destroy or impair the effectiveness of adhesive 14 in securing the drug delivery device to the skin.
- Another advantageous characteristic of the drug delivery device herein is its ability to maintain continuous contact between the drug composition and the skin thus assuring that the drug will be constantly available at the site of its administration.
- the useful foams possess a density of from about 0.8 to about 8.0 and preferably from about 1.2 to about 4.8 lb/ft, a number of pores per inch of from about 30 to about 120 and preferably from about 60 to about 90, and can be fully or partially reticulated or nonreticulated.
- the average thickness of the foam layer can vary from about 30 to about 100 mils and for many applications is preferably from about 40 to about 70 mils.
- Suitable foams that can be employed herein include the untreated oleophilic (i.e, hydrophobic) open cell polyurethane foams disclosed in U.S. Patent No. 5,352,711.
- Pressure sensitive adhesive 14 can be selected from any of the known and conventional medical grade adhesives, e.g., those based on polyacrylic, polyvinylether, or polyurethane resins. It is an essential requirement that the amount of adhesive 14 applied to zone 15 of foam layer 13 be sufficient to achieve an acceptable level of adhesion of drug delivery device 10 to the skin but, as previously stated, with a resulting peel strength that is sufficiently below the bond strength between the barrier and foam layers. The amount of adhesive that will satisfy these criteria can be readily determined by simple and routine testing. Ordinarily, a medical grade polyacrylic adhesive such as Durotak ® (National Starch & Chemical Company, Bridgewater, NJ) or Gelva ® (Monsanto Inc., St.
- Durotak ® National Starch & Chemical Company, Bridgewater, NJ
- Gelva ® Monsanto Inc., St.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98926076A EP0984781A1 (en) | 1997-05-27 | 1998-05-26 | Analgesic drug composition containing a capsaicinoid and potentiator therefor |
AU77993/98A AU7799398A (en) | 1997-05-27 | 1998-05-26 | Analgesic drug composition containing a capsaicinoid and potentiator therefor |
CA002291335A CA2291335A1 (en) | 1997-05-27 | 1998-05-26 | Analgesic drug composition containing a capsaicinoid and potentiator therefor |
JP50086299A JP2002514221A (en) | 1997-05-27 | 1998-05-26 | Analgesic composition containing capsaicinoid and enhancer thereof |
US09/441,268 US6277398B1 (en) | 1997-05-27 | 1999-11-16 | Analgesic drug composition containing a capsaicinoid and potentiator therefor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4831497P | 1997-05-27 | 1997-05-27 | |
US60/048,314 | 1997-05-27 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/441,268 Continuation US6277398B1 (en) | 1997-05-27 | 1999-11-16 | Analgesic drug composition containing a capsaicinoid and potentiator therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998053825A1 true WO1998053825A1 (en) | 1998-12-03 |
Family
ID=21953884
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/010769 WO1998053825A1 (en) | 1997-05-27 | 1998-05-26 | Analgesic drug composition containing a capsaicinoid and potentiator therefor |
Country Status (6)
Country | Link |
---|---|
US (1) | US6277398B1 (en) |
EP (1) | EP0984781A1 (en) |
JP (1) | JP2002514221A (en) |
AU (1) | AU7799398A (en) |
CA (1) | CA2291335A1 (en) |
WO (1) | WO1998053825A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000067730A1 (en) * | 1999-05-07 | 2000-11-16 | U.S. Dermatologics, Inc. | Drug delivery device |
DE10056009A1 (en) * | 2000-11-11 | 2002-05-16 | Beiersdorf Ag | Well tolerated plaster for controlled delivery of hyperemic agents, having active agent-containing matrix comprising polyisobutylene, amorphous poly-alpha-olefin and filler |
US6444440B1 (en) | 1997-03-07 | 2002-09-03 | Human Genome Sciences, Inc. | Vanilloid receptor-2 |
US6906178B2 (en) | 1998-08-11 | 2005-06-14 | Human Genome Sciences, Inc. | Vanilloid receptor-2 |
WO2006105481A1 (en) * | 2005-03-30 | 2006-10-05 | Neurogesx, Inc. | Low-concentration capsaicin patch and methods for treating neuropathic pain |
WO2009085302A2 (en) | 2007-12-28 | 2009-07-09 | Newmedical Technology, Inc. | Method and multilayered device for controlled topical delivery of therapeutic agents to the skin |
US7943166B2 (en) | 2003-04-10 | 2011-05-17 | Neurogesx, Inc. | Methods and compositions for administration of TRPV1 agonists |
US8367733B2 (en) | 2002-12-18 | 2013-02-05 | Vallinex, Inc. | Infiltration of capsaicin into surgical sites and open wounds |
US8420600B2 (en) | 2002-12-18 | 2013-04-16 | Vallinex, Inc. | Injectable capsaicin |
US8591940B2 (en) | 2004-01-02 | 2013-11-26 | New Medical Technology Inc. | Method of treating scar tissue |
US9861590B2 (en) | 2010-10-19 | 2018-01-09 | Covidien Lp | Self-supporting films for delivery of therapeutic agents |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004529079A (en) * | 2000-12-15 | 2004-09-24 | ファルマシア・コーポレーション | Selective COX-2 inhibition by plant extracts |
US7332182B2 (en) | 2001-08-06 | 2008-02-19 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant |
US7842307B2 (en) | 2001-08-06 | 2010-11-30 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent |
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
US7157103B2 (en) | 2001-08-06 | 2007-01-02 | Euro-Celtique S.A. | Pharmaceutical formulation containing irritant |
EP1450824A4 (en) * | 2001-11-02 | 2005-09-28 | Elan Corp Plc | Pharmaceutical composition |
AU2003228654A1 (en) * | 2002-04-29 | 2003-11-17 | The General Hospital Corporation | Compositions and methods for preventing abuse of orally administered medications |
US20040109886A1 (en) * | 2002-08-27 | 2004-06-10 | Larry Rigby | Methods and apparatus for transdermal delivery of abusable drugs with a deterrent agent |
WO2004022002A2 (en) * | 2002-09-09 | 2004-03-18 | Endo Pharmaceuticals Inc. | Combined immediate release and extended release analgesic composition |
EP1551402A4 (en) * | 2002-09-23 | 2009-05-27 | Verion Inc | Abuse-resistant pharmaceutical compositions |
JP3717484B2 (en) * | 2003-03-03 | 2005-11-16 | ファナック株式会社 | Molding information printing device |
WO2004092122A2 (en) * | 2003-04-08 | 2004-10-28 | Algorx Pharmaceuticals, Inc. | Preparation and purification of synthetic capsaicin |
JP5148271B2 (en) * | 2004-06-02 | 2013-02-20 | ニューロジズエックス,インコーポレーテッド | Formulations containing capsaicinoids, local anesthetics and / or antipruritics for pain treatment |
PT1765292T (en) | 2004-06-12 | 2017-12-29 | Collegium Pharmaceutical Inc | Abuse-deterrent drug formulations |
US7704522B2 (en) | 2004-09-08 | 2010-04-27 | Clyde Morgan | Topical medicament |
EA200701131A1 (en) * | 2004-11-24 | 2007-12-28 | Алгоркс Фармасьютикалз, Инк. | PREPARATIVE FORM OF CAPSAICINOIDE AND METHODS OF ITS APPLICATION |
JP2006206471A (en) | 2005-01-26 | 2006-08-10 | Nitto Denko Corp | Tape preparation |
CN101189000A (en) * | 2005-02-14 | 2008-05-28 | 纽罗吉斯克斯公司 | Device for delivery of TRPV1 agonists |
US7282224B1 (en) | 2006-06-09 | 2007-10-16 | Guthy-Renker Corporation | Pain relief composition |
US7645767B2 (en) | 2006-08-31 | 2010-01-12 | Trinity Laboratories, Inc. | Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy |
US20080107747A1 (en) * | 2006-10-23 | 2008-05-08 | Roederer Joy E | Pain relief composition |
US20080103102A1 (en) | 2006-10-27 | 2008-05-01 | Bmb Patent Holding Corporation | Therapeutic compositions and methods of treatment with capsianoside-type compounds |
US9216171B2 (en) * | 2009-05-07 | 2015-12-22 | University Of Cincinnati | Methods of preventing ischemic injury using peripheral nociceptive stimulation |
US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
ME02874B (en) | 2010-12-22 | 2018-04-20 | Purdue Pharma Lp | Encased tamper resistant controlled release dosage forms |
AU2011346758C1 (en) | 2010-12-23 | 2015-09-03 | Purdue Pharma L.P. | Tamper resistant solid oral dosage forms |
BR112015017451B1 (en) | 2013-02-05 | 2023-01-10 | Purdue Pharma L.P. | TAMPER-RESISTANT PHARMACEUTICAL FORMULATIONS |
US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
WO2017222575A1 (en) | 2016-06-23 | 2017-12-28 | Collegium Pharmaceutical, Inc. | Process of making more stable abuse-deterrent oral formulations |
CA3041121A1 (en) | 2016-11-02 | 2018-05-11 | Centrexion Therapeutics Corporation | Stable aqueous capsaicin injectable formulations and medical uses thereof |
JP7282736B2 (en) | 2017-07-20 | 2023-05-29 | セントレクシオン セラピューティクス コーポレイション | Methods and compositions for treating pain using capsaicin |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4455146A (en) * | 1979-04-03 | 1984-06-19 | Hisamitsu Pharmaceutical Co., Ltd. | Novel plasters |
US4557934A (en) * | 1983-06-21 | 1985-12-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one |
US4599342A (en) * | 1984-01-16 | 1986-07-08 | The Procter & Gamble Company | Pharmaceutical products providing enhanced analgesia |
US5273757A (en) * | 1987-09-01 | 1993-12-28 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Apparatus for the delivery of substances, processes for the production thereof and use thereof |
US5332576A (en) * | 1991-02-27 | 1994-07-26 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US5336213A (en) * | 1992-04-08 | 1994-08-09 | International Medical Associates, Inc. | Selectable dosage transdermal delivery system |
US5505958A (en) * | 1994-10-31 | 1996-04-09 | Algos Pharmaceutical Corporation | Transdermal drug delivery device and method for its manufacture |
US5589180A (en) * | 1989-03-17 | 1996-12-31 | Hind Health Care, Inc. | Method for treating nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia) by topical application of lidocaine |
WO1997002273A1 (en) * | 1995-07-05 | 1997-01-23 | The Procter & Gamble Company | Warming compounds |
WO1997004780A2 (en) * | 1995-08-02 | 1997-02-13 | Virginia Commonwealth University | Pain-alleviating drug composition and method for alleviating pain |
WO1997010815A1 (en) * | 1995-09-22 | 1997-03-27 | Frome Bruce M | The preparation of topical regional compositions for the relief of pain |
WO1998000117A2 (en) * | 1996-07-03 | 1998-01-08 | Algos Pharmaceutical Corporation | Nonocclusive drug delivery device and process for its manufacture |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4446140A (en) * | 1981-12-10 | 1984-05-01 | Nelson Research & Development Company | Method and composition for treating mouth pain |
US4681897A (en) * | 1984-01-16 | 1987-07-21 | The Procter & Gamble Company | Pharmaceutical products providing enhanced analgesia |
-
1998
- 1998-05-26 AU AU77993/98A patent/AU7799398A/en not_active Abandoned
- 1998-05-26 JP JP50086299A patent/JP2002514221A/en active Pending
- 1998-05-26 WO PCT/US1998/010769 patent/WO1998053825A1/en not_active Application Discontinuation
- 1998-05-26 CA CA002291335A patent/CA2291335A1/en not_active Abandoned
- 1998-05-26 EP EP98926076A patent/EP0984781A1/en not_active Withdrawn
-
1999
- 1999-11-16 US US09/441,268 patent/US6277398B1/en not_active Expired - Lifetime
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4455146A (en) * | 1979-04-03 | 1984-06-19 | Hisamitsu Pharmaceutical Co., Ltd. | Novel plasters |
US4557934A (en) * | 1983-06-21 | 1985-12-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one |
US4599342A (en) * | 1984-01-16 | 1986-07-08 | The Procter & Gamble Company | Pharmaceutical products providing enhanced analgesia |
US5273757A (en) * | 1987-09-01 | 1993-12-28 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Apparatus for the delivery of substances, processes for the production thereof and use thereof |
US5589180A (en) * | 1989-03-17 | 1996-12-31 | Hind Health Care, Inc. | Method for treating nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia) by topical application of lidocaine |
US5332576A (en) * | 1991-02-27 | 1994-07-26 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US5336213A (en) * | 1992-04-08 | 1994-08-09 | International Medical Associates, Inc. | Selectable dosage transdermal delivery system |
US5505958A (en) * | 1994-10-31 | 1996-04-09 | Algos Pharmaceutical Corporation | Transdermal drug delivery device and method for its manufacture |
WO1997002273A1 (en) * | 1995-07-05 | 1997-01-23 | The Procter & Gamble Company | Warming compounds |
WO1997004780A2 (en) * | 1995-08-02 | 1997-02-13 | Virginia Commonwealth University | Pain-alleviating drug composition and method for alleviating pain |
WO1997010815A1 (en) * | 1995-09-22 | 1997-03-27 | Frome Bruce M | The preparation of topical regional compositions for the relief of pain |
WO1998000117A2 (en) * | 1996-07-03 | 1998-01-08 | Algos Pharmaceutical Corporation | Nonocclusive drug delivery device and process for its manufacture |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6444440B1 (en) | 1997-03-07 | 2002-09-03 | Human Genome Sciences, Inc. | Vanilloid receptor-2 |
US6906178B2 (en) | 1998-08-11 | 2005-06-14 | Human Genome Sciences, Inc. | Vanilloid receptor-2 |
WO2000067730A1 (en) * | 1999-05-07 | 2000-11-16 | U.S. Dermatologics, Inc. | Drug delivery device |
US6277401B1 (en) | 1999-05-07 | 2001-08-21 | U.S. Dermatologics, Inc. | Drug delivery device |
DE10056009A1 (en) * | 2000-11-11 | 2002-05-16 | Beiersdorf Ag | Well tolerated plaster for controlled delivery of hyperemic agents, having active agent-containing matrix comprising polyisobutylene, amorphous poly-alpha-olefin and filler |
US8367733B2 (en) | 2002-12-18 | 2013-02-05 | Vallinex, Inc. | Infiltration of capsaicin into surgical sites and open wounds |
US8420600B2 (en) | 2002-12-18 | 2013-04-16 | Vallinex, Inc. | Injectable capsaicin |
US8734770B2 (en) | 2003-04-10 | 2014-05-27 | Acorda Therapeutics, Inc. | Methods and compositions for administration of TRPV1 agonists |
US7943166B2 (en) | 2003-04-10 | 2011-05-17 | Neurogesx, Inc. | Methods and compositions for administration of TRPV1 agonists |
US8263093B2 (en) | 2003-04-10 | 2012-09-11 | Neurogesx, Inc. | Methods and compositions for administration of TRPV1 agonists |
US8273390B2 (en) | 2003-04-10 | 2012-09-25 | Neurogesx, Inc. | Methods and compositions for administration of TRPV1 agonists |
US9750707B2 (en) | 2003-04-10 | 2017-09-05 | Acorda Therapeutics, Inc. | Methods and compositions for administration of TRPV1 agonists |
US10653647B2 (en) | 2003-04-10 | 2020-05-19 | Grt Us Holding, Inc. | Methods and compositions for administration of TRPV1 agonists |
US8591940B2 (en) | 2004-01-02 | 2013-11-26 | New Medical Technology Inc. | Method of treating scar tissue |
WO2006105481A1 (en) * | 2005-03-30 | 2006-10-05 | Neurogesx, Inc. | Low-concentration capsaicin patch and methods for treating neuropathic pain |
EP2237772A4 (en) * | 2007-12-28 | 2013-01-30 | Newmedical Technologies Inc | Method and multilayered device for controlled topical delivery of therapeutic agents to the skin |
EP2237772A2 (en) * | 2007-12-28 | 2010-10-13 | Newmedical Technologies, Inc. | Method and multilayered device for controlled topical delivery of therapeutic agents to the skin |
WO2009085302A2 (en) | 2007-12-28 | 2009-07-09 | Newmedical Technology, Inc. | Method and multilayered device for controlled topical delivery of therapeutic agents to the skin |
US9861590B2 (en) | 2010-10-19 | 2018-01-09 | Covidien Lp | Self-supporting films for delivery of therapeutic agents |
Also Published As
Publication number | Publication date |
---|---|
JP2002514221A (en) | 2002-05-14 |
US6277398B1 (en) | 2001-08-21 |
EP0984781A1 (en) | 2000-03-15 |
CA2291335A1 (en) | 1998-12-03 |
AU7799398A (en) | 1998-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6277398B1 (en) | Analgesic drug composition containing a capsaicinoid and potentiator therefor | |
US5665378A (en) | Transdermal therapeutic formulation | |
US6277401B1 (en) | Drug delivery device | |
US4806341A (en) | Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration | |
KR101407131B1 (en) | Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein | |
Pascoe | Opioid analgesics | |
AU685106B2 (en) | Method for treating emotional or mental illness and emotional or mental illness concomitant with seizures | |
KR101159828B1 (en) | Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer | |
EP1239845B1 (en) | Hydroxide-releasing agents as skin permeation enhancers | |
US20030224035A1 (en) | Hydroxide-releasing agents as skin permeation enhancers | |
RU2004106619A (en) | COMPOSITIONS OF AN OPIOID AGONIST CONTAINING A RELEASABLE AND ISOLATED ANTAGONIST | |
RU2000101024A (en) | OPOID ANALGETICS WITH CONTROLLED RELEASE OF ACTIVE SUBSTANCES | |
CZ20023030A3 (en) | Pharmaceutical preparation | |
WO2003015748A3 (en) | Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds | |
US20070202155A1 (en) | Low dose no donor-containing transdermal patch | |
WO2001013909A3 (en) | Compositions and methods for treating opiate intolerance | |
WO2007099966A1 (en) | Transdermal absorption preparation | |
KR950703939A (en) | PLA FOR FOR TRANSLATEMAL ADMINISTRATION OF VOLATILE PHARAMACEUTICALLY ACTIVE, CHEMICALLY ALKALINE INGREDIENS, AND PROCESS FOR PRODUCING THE SAME | |
US20070248657A1 (en) | Multi-compartment transdermal pain control device | |
US20080160068A1 (en) | Method for a Medicinal Combination Treatment, and Medicament Combinations Suitable Therefor | |
Jacobson et al. | Immobilization of African elephants with carfentanil and antagonism with nalmefene and diprenorphine | |
JP2003176227A (en) | Pharmaceutical composition, method for alleviating tobacco-smoking withdrawal symptom in patient refraining from smoking, and kit for alleviating tobacco- smoking withdrawal symptom in patient | |
US4730007A (en) | Novel analgesic compositions | |
CA2234969A1 (en) | Adhesive patch for lithium controlled release | |
CN1226163A (en) | Formulation for treatment and/or prevention of dementia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09441268 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2291335 Country of ref document: CA Ref country code: CA Ref document number: 2291335 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998926076 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998926076 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998926076 Country of ref document: EP |